Xiaoming Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoming Jia has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Salim Shahbuddin Virani
Aga Khan University
14 shared publications Mahmoud Al Rifai
Baylor College of Medicine, Houston, TX, USA
6 shared publications- Vijay Nambi
Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, USA
6 shared publications Christie M. Ballantyne
Baylor College of Medicine, Houston, TX, USA
5 shared publications- Christie M. Ballantyne
Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.).
5 shared publications Mahboob Alam
5 shared publications
Latest Publications
- 13 December 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1-9
Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function – a Meta-Analysis of Contemporary Randomized Controlled Trials
Background In the contemporary reperfusion era, the benefit of beta-blocker therapy in patients after acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) remains unclear. Recently conducted clinical trials have demonstrated mixed results about the clinical benefit of beta-blockers after myocardial infarction in pooled populations of patients with mildly reduced (LVEF 40–49%) or preserved LVEF. However, new evidence suggests a consistent benefit of beta-blocker therapy in patients specifically with mildly reduced LVEF. We aimed to assess the efficacy of beta-blockers in patients with recent myocardial infarction and mildly reduced or preserved LVEF, as well as specifically with preserved LVEF. Methods We conducted a systematic review of recent randomized controlled trials that evaluated the effects of oral beta-blocker therapy in patients with AMI who had either mildly reduced LVEF or preserved LVEF and with follow-up data of at least 1 year. Using a Mantel-Haenszel random effects model, we computed risk ratios (RR) with 95% confidence intervals for the primary composite outcome along with individual outcomes of death, re-infarction, and heart failure between patients with and without beta-blocker therapy. We performed analysis of the pooled overall study population, which included patients with mildly reduced LVEF and preserved LVEF, as well as performed subgroup analysis of patients with preserved versus mildly reduced LVEF and among men versus women. Results 19,826 patients with mildly reduced or preserved LVEF were included in the meta-analysis. Overall, 9,892 patients were assigned to beta-blockers and 9,934 to no beta-blockers. Among the pooled population, we did not demonstrate significant differences between the beta-blocker group and the control group for the primary composite outcome (RR 0.93, 95% CI 0.83–1.04), all-cause death, reinfarction, or heart failure. We further did not detect differences in the primary outcome by sex. While there was no differences in the primary composite outcome among patients with preserved LVEF (RR 0.96, 95% CI 0.86–1.08), there was reduction in risk observed among individuals with mildly reduced LVEF (RR 0.76, 95% CI 0.61–0.94). Conclusion Oral beta-blocker therapy was not associated with a reduction in the primary composite outcome in patients with preserved LVEF. This contrasts with their established benefit in patients with reduced LVEF and the growing evidence of benefit in those with mildly reduced LVEF.
- 13 December 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1-9
Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function – a Meta-Analysis of Contemporary Randomized Controlled Trials
Background In the contemporary reperfusion era, the benefit of beta-blocker therapy in patients after acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) remains unclear. Recently conducted clinical trials have demonstrated mixed results about the clinical benefit of beta-blockers after myocardial infarction in pooled populations of patients with mildly reduced (LVEF 40–49%) or preserved LVEF. However, new evidence suggests a consistent benefit of beta-blocker therapy in patients specifically with mildly reduced LVEF. We aimed to assess the efficacy of beta-blockers in patients with recent myocardial infarction and mildly reduced or preserved LVEF, as well as specifically with preserved LVEF. Methods We conducted a systematic review of recent randomized controlled trials that evaluated the effects of oral beta-blocker therapy in patients with AMI who had either mildly reduced LVEF or preserved LVEF and with follow-up data of at least 1 year. Using a Mantel-Haenszel random effects model, we computed risk ratios (RR) with 95% confidence intervals for the primary composite outcome along with individual outcomes of death, re-infarction, and heart failure between patients with and without beta-blocker therapy. We performed analysis of the pooled overall study population, which included patients with mildly reduced LVEF and preserved LVEF, as well as performed subgroup analysis of patients with preserved versus mildly reduced LVEF and among men versus women. Results 19,826 patients with mildly reduced or preserved LVEF were included in the meta-analysis. Overall, 9,892 patients were assigned to beta-blockers and 9,934 to no beta-blockers. Among the pooled population, we did not demonstrate significant differences between the beta-blocker group and the control group for the primary composite outcome (RR 0.93, 95% CI 0.83–1.04), all-cause death, reinfarction, or heart failure. We further did not detect differences in the primary outcome by sex. While there was no differences in the primary composite outcome among patients with preserved LVEF (RR 0.96, 95% CI 0.86–1.08), there was reduction in risk observed among individuals with mildly reduced LVEF (RR 0.76, 95% CI 0.61–0.94). Conclusion Oral beta-blocker therapy was not associated with a reduction in the primary composite outcome in patients with preserved LVEF. This contrasts with their established benefit in patients with reduced LVEF and the growing evidence of benefit in those with mildly reduced LVEF.
- Open Access
- 12 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e042140
Heart Failure and Death in Older Adults With Elevated Cardiac Biomarkers But Without Risk Factors: The Atherosclerosis Risk in Communities Study
- 12 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e042140
Open AccessHeart Failure and Death in Older Adults With Elevated Cardiac Biomarkers But Without Risk Factors: The Atherosclerosis Risk in Communities Study
- 28 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (2) , 926-933
Optimal Stenting Technique for Lesions at the Ostium of the Left Anterior Descending Artery: A Systematic Review and Meta‐Analysis
Background: Ostial lesions of the left anterior descending (LAD) artery present unique challenges for interventional cardiologists. The two principal techniques for percutaneous coronary intervention (PCI) of ostial LAD lesions are ostial stenting (OS) and cross‐over stenting (CS). Current data comparing the efficacy of these techniques have been mixed. Aims: Determine whether there are differences in efficacy between CS and OS for PCI of ostial LAD lesions. Methods: We performed a systematic review of studies comparing CS and OS techniques regarding long‐term outcomes (≥ 1 year). Using the Mantel‐Haenszel random effects model, we computed relative risk (RR) with 95% confidence intervals (CI) for major adverse cardiovascular events (MACE), death, myocardial infarction (MI), target lesion revascularization (TLR), and stent thrombosis (ST) between CS and OS groups. For significant outcomes, a subgroup analysis was performed, dividing studies by percent intravascular ultrasound (IVUS) use (> 50% vs. 50%). Results: Eight cohort studies with a total of 1448 participants were included in the meta‐analysis. CS was favored with respect to TLR (5.5% vs. 10.6%; RR 0.57, 95% CI 0.34−0.95, p = 0.03) and ST (0.9% vs. 4.3%; RR 0.34, 95% CI 0.13−0.93, p = 0.04). There was no significant association between stenting technique with MACE, death or MI, though significant heterogeneity was observed in analyses of these outcomes. In subgroup analysis, significant association favoring CS in TLR and ST was observed in the lower IVUS use but not in the higher IVUS use subgroup. Conclusion: Our meta‐analysis suggests that CS is associated with lower long‐term risk for TLR and ST compared to OS in PCI of ostial LAD lesions, especially if intravascular imaging is not available.
- 28 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (2) , 926-933
Optimal Stenting Technique for Lesions at the Ostium of the Left Anterior Descending Artery: A Systematic Review and Meta‐Analysis
Background: Ostial lesions of the left anterior descending (LAD) artery present unique challenges for interventional cardiologists. The two principal techniques for percutaneous coronary intervention (PCI) of ostial LAD lesions are ostial stenting (OS) and cross‐over stenting (CS). Current data comparing the efficacy of these techniques have been mixed. Aims: Determine whether there are differences in efficacy between CS and OS for PCI of ostial LAD lesions. Methods: We performed a systematic review of studies comparing CS and OS techniques regarding long‐term outcomes (≥ 1 year). Using the Mantel‐Haenszel random effects model, we computed relative risk (RR) with 95% confidence intervals (CI) for major adverse cardiovascular events (MACE), death, myocardial infarction (MI), target lesion revascularization (TLR), and stent thrombosis (ST) between CS and OS groups. For significant outcomes, a subgroup analysis was performed, dividing studies by percent intravascular ultrasound (IVUS) use (> 50% vs. 50%). Results: Eight cohort studies with a total of 1448 participants were included in the meta‐analysis. CS was favored with respect to TLR (5.5% vs. 10.6%; RR 0.57, 95% CI 0.34−0.95, p = 0.03) and ST (0.9% vs. 4.3%; RR 0.34, 95% CI 0.13−0.93, p = 0.04). There was no significant association between stenting technique with MACE, death or MI, though significant heterogeneity was observed in analyses of these outcomes. In subgroup analysis, significant association favoring CS in TLR and ST was observed in the lower IVUS use but not in the higher IVUS use subgroup. Conclusion: Our meta‐analysis suggests that CS is associated with lower long‐term risk for TLR and ST compared to OS in PCI of ostial LAD lesions, especially if intravascular imaging is not available.
- Open Access
- 21 January 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- p. 1-2
Which Therapies Should Be Initiated After Optimizing Statins? A Multi-pillar Strategy for ASCVD Risk Reduction
- 21 January 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- p. 1-2
Open AccessWhich Therapies Should Be Initiated After Optimizing Statins? A Multi-pillar Strategy for ASCVD Risk Reduction
- Open Access
- 5 September 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (5) , 973-975
Use of Early Intravenous Beta Blockers in Patients with Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure—Revival or Requiem?
- 5 September 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (5) , 973-975
Open AccessUse of Early Intravenous Beta Blockers in Patients with Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure—Revival or Requiem?
- 23 July 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (2) , 100-112
Early-onset atherosclerotic cardiovascular disease
Recent trends indicate a concerning increase in early-onset atherosclerotic cardiovascular disease (ASCVD) among younger individuals (men aged <55 years women aged <65 years). These findings highlight the pathobiology of ASCVD as a disease process that begins early in life and underscores the need for more tailored screening methods and preventive strategies. Increasing attention has been placed on the growing burden of traditional cardiometabolic risk factors in young individuals while also recognizing unique factors that mediate risk of pre-mature atherosclerosis in this demographic such as substance use, socioeconomic disparities, adverse pregnancy outcomes, and chronic inflammatory states that contribute to the increasing incidence of early ASCVD. Additionally, mounting evidence has pointed out significant disparities in the diagnosis and management of early ASCVD and cardiovascular outcomes based on sex and race. Moving towards a more personalized approach, emerging data and technological developments using diverse tools such as polygenic risk scores and coronary artery calcium scans have shown potential in earlier detection of ASCVD risk. Thus, we review current evidence on causal risk factors that drive the increase in early ASCVD and highlight emerging tools to improve ASCVD risk assessment in young individuals.
- 23 July 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (2) , 100-112
Early-onset atherosclerotic cardiovascular disease
Recent trends indicate a concerning increase in early-onset atherosclerotic cardiovascular disease (ASCVD) among younger individuals (men aged <55 years women aged <65 years). These findings highlight the pathobiology of ASCVD as a disease process that begins early in life and underscores the need for more tailored screening methods and preventive strategies. Increasing attention has been placed on the growing burden of traditional cardiometabolic risk factors in young individuals while also recognizing unique factors that mediate risk of pre-mature atherosclerosis in this demographic such as substance use, socioeconomic disparities, adverse pregnancy outcomes, and chronic inflammatory states that contribute to the increasing incidence of early ASCVD. Additionally, mounting evidence has pointed out significant disparities in the diagnosis and management of early ASCVD and cardiovascular outcomes based on sex and race. Moving towards a more personalized approach, emerging data and technological developments using diverse tools such as polygenic risk scores and coronary artery calcium scans have shown potential in earlier detection of ASCVD risk. Thus, we review current evidence on causal risk factors that drive the increase in early ASCVD and highlight emerging tools to improve ASCVD risk assessment in young individuals.
- Open Access
- 13 February 2024
- Published by S. Karger AG in Cardiology
- Vol. 149 (3) , 196-204
Intravascular Ultrasound-Guided versus Angiography-Guided Percutaneous Coronary Intervention for Stent Thrombosis Elevation Myocardial Infarction: An Updated Systematic Review and Meta-Analysis
Introduction: Intravascular ultrasound (IVUS) provides intra-procedural guidance in optimizing percutaneous coronary interventions (PCI) and has been shown to improve clinical outcomes in stent implantation. However, current data on the benefit of IVUS during PCI in ST-elevation myocardial infarction (STEMI) patients is mixed. We performed meta-analysis pooling available data assessing IVUS-guided versus angiography-guided PCI in STEMI patients. Methods: We conducted a systematic search on PubMed and Embase for studies comparing IVUS versus angiography-guided PCI in STEMI. Mantel-Haenszel random effects model was used to calculate risk ratios (RRs) with 95% confidence intervals (CIs) for outcomes of major adverse cardiovascular events (MACEs), death, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST) and in-hospital mortality. Results: A total of 8 studies including 336,649 individuals presenting with STEMI were included for the meta-analysis. Follow-up ranged from 11 to 60 months. We found significant association between IVUS-guided PCI with lower risk for MACE (RR 0.82, 95% CI 0.76–0.90) compared with angiography-guided PCI. We also found significant association between IVUS-guided PCI with lower risk for death, MI, TVR, and in-hospital mortality but not ST. Conclusion: In our meta-analysis, IVUS-guided compared with angiography-guided PCI was associated with improved long-term and short-term clinical outcomes in STEMI patients.
- 13 February 2024
- Published by S. Karger AG in Cardiology
- Vol. 149 (3) , 196-204
Open AccessIntravascular Ultrasound-Guided versus Angiography-Guided Percutaneous Coronary Intervention for Stent Thrombosis Elevation Myocardial Infarction: An Updated Systematic Review and Meta-Analysis
Introduction: Intravascular ultrasound (IVUS) provides intra-procedural guidance in optimizing percutaneous coronary interventions (PCI) and has been shown to improve clinical outcomes in stent implantation. However, current data on the benefit of IVUS during PCI in ST-elevation myocardial infarction (STEMI) patients is mixed. We performed meta-analysis pooling available data assessing IVUS-guided versus angiography-guided PCI in STEMI patients. Methods: We conducted a systematic search on PubMed and Embase for studies comparing IVUS versus angiography-guided PCI in STEMI. Mantel-Haenszel random effects model was used to calculate risk ratios (RRs) with 95% confidence intervals (CIs) for outcomes of major adverse cardiovascular events (MACEs), death, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST) and in-hospital mortality. Results: A total of 8 studies including 336,649 individuals presenting with STEMI were included for the meta-analysis. Follow-up ranged from 11 to 60 months. We found significant association between IVUS-guided PCI with lower risk for MACE (RR 0.82, 95% CI 0.76–0.90) compared with angiography-guided PCI. We also found significant association between IVUS-guided PCI with lower risk for death, MI, TVR, and in-hospital mortality but not ST. Conclusion: In our meta-analysis, IVUS-guided compared with angiography-guided PCI was associated with improved long-term and short-term clinical outcomes in STEMI patients.
- 7 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (Suppl_1)
Abstract 11889: Ischemic Evaluation in Patients Presenting With Advanced Atrioventricular Block - Experience From a Large County Health System
- 7 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (Suppl_1)
Abstract 11889: Ischemic Evaluation in Patients Presenting With Advanced Atrioventricular Block - Experience From a Large County Health System